Literature DB >> 32800657

Effects of melatonin to arecoline-induced reactive oxygen species production and DNA damage in oral squamous cell carcinoma.

Yin-Hwa Shih1, Kuo-Chou Chiu2, Tong-Hong Wang3, Wan-Chen Lan4, Bi-He Tsai5, Li-Jia Wu6, Shih-Min Hsia7, Tzong-Ming Shieh8.   

Abstract

BACKGROUND/
PURPOSE: Arecoline, the major alkaloid of areca nut, is known to induce reactive oxygen species (ROS) and DNA damage during oral cancer progression. This study aim to evaluate whether melatonin, an antioxidant, supported or repressed the arecoline-induced carcinogenesis phenotypes in oral squamous cell carcinoma (OSCC).
METHODS: The cytotoxicity of arecoline or melatonin treatment alone and their co-treatment in the OSCC cell line OEC-M1 were analyzed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cell cycle, cell death, and total ROS production were analyzed using flow cytometer. The protein expression was determined using western blot analysis. The genotoxicity and mutation rate were determined using micronucleus assay and hypoxanthine phosphoribosyl transferase (HPRT) forward mutation assay, respectively, in CHO-K1 cells. The ataxia telangiectasia mutated (ATM) promoter activity and DNA repair ability were determined through reporter assay.
RESULTS: The result showed that both the arecoline and melatonin induced ROS production and antioxidant enzymes expression. Melatonin treatment enhanced arecoline-induced ROS production, cytotoxicity, G2/M phase arrest, and cell apoptosis in OSCC cells. On the other hand, melatonin treatment activated DNA repair activity to reverse arecoline-induced DNA damage and mutation.
CONCLUSION: These results indicated that melatonin is a potential chemopreventive agent for betel quid chewers to prevent OSCC initiation and progression.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Arecoline; DNA repair; Melatonin; Oral squamous cell carcinoma (OSCC); Reactive oxygen species (ROS)

Year:  2020        PMID: 32800657     DOI: 10.1016/j.jfma.2020.07.037

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  4 in total

1.  A Case Study on Integrating a New Key Event Into an Existing Adverse Outcome Pathway on Oxidative DNA Damage: Challenges and Approaches in a Data-Rich Area.

Authors:  Elizabeth Huliganga; Francesco Marchetti; Jason M O'Brien; Vinita Chauhan; Carole L Yauk
Journal:  Front Toxicol       Date:  2022-04-28

Review 2.  Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.

Authors:  Wamidh H Talib; Ahmad Riyad Alsayed; Alaa Abuawad; Safa Daoud; Asma Ismail Mahmod
Journal:  Molecules       Date:  2021-04-25       Impact factor: 4.411

Review 3.  Use of Melatonin in Cancer Treatment: Where Are We?

Authors:  Leilei Wang; Chuan Wang; Wing Shan Choi
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 4.  Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments.

Authors:  Yen-Wen Shen; Yin-Hwa Shih; Lih-Jyh Fuh; Tzong-Ming Shieh
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.